A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

Tabrez, Shams; Ali, Murtaza; Jabir, Nasimudeen R.; Firoz, Chelapram K.; Ashraf, Ghulam Md; Hindawi, Salwa; Damanhouri, Ghazi A.; Alama, Mohammed Nabil

doi:10.1002/iub.1637

Cited by 25 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a self-stimulating loop, the microglia can also secrete IL-12, activating NK and stimulating T cells 52 . IL-10 is a multifunctional immune cytokine with anti-angiogenic properties 53,54 . Finally, cytokines like IL-1β and TNFα can suppress tumors via stimulation of cell-mediated humoral immune reaction 55 .…”

Section: Discussionmentioning

confidence: 99%

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

et al. 2019

View full text Add to dashboard Cite

Brain glioma treatment with checkpoint inhibitor antibodies to cytotoxic T-lymphocyteassociated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was largely unsuccessful due to their inability to cross blood-brain barrier (BBB). Here we describe targeted nanoscale immunoconjugates (NICs) on natural biopolymer scaffold, poly(β-L-malic acid), with covalently attached a-CTLA-4 or a-PD-1 for systemic delivery across the BBB and activation of local brain anti-tumor immune response. NIC treatment of mice bearing intracranial GL261 glioblastoma (GBM) results in an increase of CD8+ T cells, NK cells and macrophages with a decrease of regulatory T cells (Tregs) in the brain tumor area. Survival of GBM-bearing mice treated with NIC combination is significantly longer compared to animals treated with single checkpoint inhibitor-bearing NICs or free a-CTLA-4 and a-PD-1. Our study demonstrates trans-BBB delivery of tumor-targeted polymer-conjugated checkpoint inhibitors as an effective GBM treatment via activation of both systemic and local privileged brain tumor immune response.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several studies have reported a mean 6 SD serum IL-10 level of 34.4 6 38.5 pg/ml (34.0 6 23.8 pg/ml in men and 34.6 6 44.4 pg/ml in women), whereas those in patients with cardiovascular disease, ST elevation myocardial infarction, or unstable angina range from 574.84 to 710.52 pg/ml (31)(32)(33)(34). We used CCK-8 to assess the effects of IL-10 (0-2000 ng/ml) on the proliferation of hBMSCs for 3 d. As shown in Supplemental Fig.…”

Section: Discussionmentioning

confidence: 99%

Concentration‐dependent, dual roles of IL‐10 in the osteogenesis of human BMSCsviaP38/MAPK and NF‐κB signaling pathways

et al. 2018

View full text Add to dashboard Cite

Microenvironmental conditions can influence the differentiation and functional roles of mesenchymal stem cells (MSCs). Recent studies have suggested that an inflammatory microenvironment can significantly affect the osteogenic differentiation of MSCs. Here, we show, for the first time, that IL-10 has concentration-dependent, dual roles in the osteogenesis of human bone marrow mesenchymal stem cells (hBMSCs). Low physiologic concentrations of IL-10 (0.01-1.0 ng/ml) activate the p38/MAPK signaling pathway to promote the osteogenesis of hBMSCs, but higher pathologic doses of IL-10 (10-100 ng/ml) inhibit p38/MAPK signaling by activating NF-κB, inhibiting osteogenesis. These results demonstrate that p38/MAPK and NF-κB signaling mediates the double-edged sword effect of IL-10 on hBMSCs. The osteogenic impairment was reversed at higher doses of IL-10 when cells were supplemented with the NF-κB inhibitor BAY11-7082. These data provide important insights into the regulatory effects of IL-10 on the biologic behavior of hBMSCs.-Chen, E., Liu, G., Zhou, X., Zhang, W., Wang, C., Hu, D., Xue, D., Pan, Z. Concentration-dependent, dual roles of IL-10 in the osteogenesis of human BMSCs via P38/MAPK and NF-κB signaling pathways.

show abstract

“…In a selfstimulating loop, the microglia can also secrete IL-12, activating NK and stimulating T cells 32 . Conversely, IL-10 is a multifunctional immune cytokine with anti-angiogenic properties 33,34 . Finally, cytokines like IL-1β and TNF-α can suppress tumors via stimulation of cell-mediated humoral immune reaction 35 .…”

Section: Discussionmentioning

confidence: 99%

Nano immunoconjugates crossing blood-brain barrier activate local brain tumor immune system for glioma treatment

Galstyan

Chiechi

Sun

et al. 2018

Preprint

View full text Add to dashboard Cite

Treatment of brain gliomas with checkpoint inhibitor antibodies to cytotoxic Tlymphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was largely unsuccessful due to their inability to cross the blood-brain barrier (BBB). We describe a new generation of nano immunoconjugates (NICs) developed on natural biopolymer scaffold, poly(β-L-malic acid), with covalently attached a-CTLA-4 and/or a-PD-1 for delivery across the BBB and activation of local brain anti-tumor immune response in glioma-bearing mice. NIC treatment of mice bearing intracranial GL261 glioblastoma (GBM) resulted in an increase of CD8+ T-cells with a decrease of T regulatory cells (Tregs) in the brain tumor area. Survival of GBM-bearing mice treated with combination of NICs was significantly longer compared to animals treated by single

show abstract

A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

Cited by 25 publications

References 38 publications

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Concentration‐dependent, dual roles of IL‐10 in the osteogenesis of human BMSCsviaP38/MAPK and NF‐κB signaling pathways

Nano immunoconjugates crossing blood-brain barrier activate local brain tumor immune system for glioma treatment

Contact Info

Product

Resources

About